Aspira Women's Health Files 8-K

Ticker: AWHL · Form: 8-K · Filed: Jun 14, 2024 · CIK: 926617

Sentiment: neutral

Topics: regulatory-disclosure, financial-statements, company-history

TL;DR

Aspira Women's Health filed an 8-K on June 14th for an event on June 13th - likely financial or regulatory news.

AI Summary

Aspira Women's Health Inc. filed an 8-K on June 14, 2024, reporting an event on June 13, 2024. The filing is categorized under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.

Why It Matters

This 8-K filing indicates a regulatory disclosure and potential financial updates for Aspira Women's Health Inc., which could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for regulatory disclosure and financial statements, not indicating immediate significant financial distress or major corporate events.

Key Players & Entities

FAQ

What specific event occurred on June 13, 2024, that necessitated this 8-K filing?

The filing does not specify the exact event that occurred on June 13, 2024, but it is categorized under Regulation FD Disclosure and Financial Statements and Exhibits.

What is the primary business of Aspira Women's Health Inc.?

Aspira Women's Health Inc. is involved in IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES, as indicated by its SIC code.

When was Aspira Women's Health Inc. incorporated and where is it headquartered?

The company is incorporated in Delaware and headquartered at 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas.

What were the previous names of Aspira Women's Health Inc.?

The company was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.

What is the SEC file number for Aspira Women's Health Inc.?

The SEC file number for Aspira Women's Health Inc. is 001-34810.

Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-06-14 16:00:12

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 13, 2024, Aspira Women's Health Inc. (the "Company") issued a press release reporting commercial and operational updates. A copy of the Company's press release is attached hereto as Exhibit 99.1.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Aspira Women's Health on June 13, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: June 14, 2024 By: /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing